Clinical trial
Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
NCT04706936 is registered in ClinicalTrials.gov with Second Affiliated Hospital, Zhejiang University, School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- April 1, 2021
- Completion date
- April 30, 2024
- Enrollment
- 25 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
relapsed or refractory multiple myeloma